Chimeric antigen receptor (CAR) T-cell therapy is effective in relapsed/refractory B-cell lymphoma. However, its use is hampered by on-target offtumor toxicities—primarily cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS)—driven by CAR Tcell activation and cytokine release. Improved management has reduced their incidence and severity. Prophylactic strategies, including corticosteroids [1] and anakinra [2,3], have emerged. In ZUMA-1 cohort 6, prophylactic corticosteroids eliminated severe CRS and reduced ICANS (18% versus 28%) without compromising response; however, concerns regarding corticosteroid burden persist [3]. In a study by Park et al. [2], prophylactic anakinra reduced grade 3 ICANS to 9.7% versus historical 28% to 38% and decreased dexamethasone use. While effective for ICANS, its impact on severe CRS appears limited [2]. Despite a favorable safety profile, its toxicities remain incompletely defined. We therefore evaluated prophylactic anakinra in CD28 based CD19 CAR T-cell therapy. We retrospectively analyzed seven high-risk non-Hodgkin lymphoma patients treated with CAR T-cell therapy at Careggi University Hospital (November 2023 to June 2024), who received prophylactic anakinra. A contemporaneous high-risk cohort meeting the same criteria but not treated served as a descriptive comparator (unmatched, nonrandomized). Analyses were descriptive only, with no formal statistical comparisons; continuous variables are reported as medians (IQR) and categorical variables as counts and percentages. Written informed consent was obtained from all patients for data collection within the EBMT registry and for off-label usage of anakinra. The study was conducted in accordance with the Declaration of Helsinki.
Safety of Prophylactic Anakinra in Patients Treated with CD28-Based CD19 Chimeric Antigen Receptor-T Cells for R/R B-Cell Lymphoma / Cutini, I., Camerini, C., Coltro, G., Gozzini, A., Simonetti, E., Giordano, M., Mirabella, G., Mazzoni, A., Matani, F., Caporale, R., Bencini, S., Peruzzi, B., Nassi, L., Puccini, B., Sordi, B., Pasquini, A., Imbriani, C., Annunziato, F., Vannucchi, A.M., Nozzoli, C.. - In: TRANSPLANTATION AND CELLULAR THERAPY. - ISSN 2666-6367. - ELETTRONICO. - 32:(2026), pp. 0-0. [10.1016/j.jtct.2026.04.049]
Safety of Prophylactic Anakinra in Patients Treated with CD28-Based CD19 Chimeric Antigen Receptor-T Cells for R/R B-Cell Lymphoma
Cutini, Ilaria;Coltro, Giacomo;Gozzini, Antonella;Giordano, Mirella;Mirabella, Gaia;Mazzoni, Alessio;Matani, Francesca;Peruzzi, Benedetta;Puccini, Benedetta;Sordi, Benedetta;Pasquini, Andrea;Imbriani, Corrado;Annunziato, Francesco;Vannucchi, Alessandro Maria;Nozzoli, Chiara
2026
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is effective in relapsed/refractory B-cell lymphoma. However, its use is hampered by on-target offtumor toxicities—primarily cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS)—driven by CAR Tcell activation and cytokine release. Improved management has reduced their incidence and severity. Prophylactic strategies, including corticosteroids [1] and anakinra [2,3], have emerged. In ZUMA-1 cohort 6, prophylactic corticosteroids eliminated severe CRS and reduced ICANS (18% versus 28%) without compromising response; however, concerns regarding corticosteroid burden persist [3]. In a study by Park et al. [2], prophylactic anakinra reduced grade 3 ICANS to 9.7% versus historical 28% to 38% and decreased dexamethasone use. While effective for ICANS, its impact on severe CRS appears limited [2]. Despite a favorable safety profile, its toxicities remain incompletely defined. We therefore evaluated prophylactic anakinra in CD28 based CD19 CAR T-cell therapy. We retrospectively analyzed seven high-risk non-Hodgkin lymphoma patients treated with CAR T-cell therapy at Careggi University Hospital (November 2023 to June 2024), who received prophylactic anakinra. A contemporaneous high-risk cohort meeting the same criteria but not treated served as a descriptive comparator (unmatched, nonrandomized). Analyses were descriptive only, with no formal statistical comparisons; continuous variables are reported as medians (IQR) and categorical variables as counts and percentages. Written informed consent was obtained from all patients for data collection within the EBMT registry and for off-label usage of anakinra. The study was conducted in accordance with the Declaration of Helsinki.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2666636726003350-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
337.5 kB
Formato
Adobe PDF
|
337.5 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



